These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34286855)

  • 1. Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy.
    Esdaille AR; Abel EJ
    Cancer; 2021 Nov; 127(21):3920-3923. PubMed ID: 34286855
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
    J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients?
    Patel HD; Clark JI; Flanigan RC
    J Urol; 2021 Jul; 206(1):4-6. PubMed ID: 33560871
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytoreductive Nephrectomy - Patient Selection Is Key.
    Motzer RJ; Russo P
    N Engl J Med; 2018 Aug; 379(5):481-482. PubMed ID: 29860908
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
    Biles MJ; Patel HD; Allaf ME
    Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors.
    Shapiro DD; Abel EJ
    Curr Opin Urol; 2019 Sep; 29(5):513-520. PubMed ID: 31305274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
    Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? No, cytoreductive nephrectomy should no longer be routinely performed.
    Kim HL
    Curr Opin Urol; 2020 Sep; 30(5):743-745. PubMed ID: 32732627
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Liu J; Moon D; Lawrentschuk N
    Eur Urol; 2023 Aug; 84(2):244-245. PubMed ID: 37088596
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
    Meza L; Chehrazi-Raffle A; Pal SK
    Curr Opin Urol; 2020 Sep; 30(5):740-742. PubMed ID: 32732626
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy.
    Capitanio U; Larcher A; Montorsi F
    BJU Int; 2019 Jul; 124(1):6-7. PubMed ID: 30656818
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytoreductive nephrectomy in the era of targeted therapies: a review.
    Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
    BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Psutka SP
    Cancer; 2020 Sep; 126(17):3912-3915. PubMed ID: 32515836
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
    Li J; Chen B; Cao D
    Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytoreductive nephrectomy: future directions.
    Margulis V; Hakimi AA
    Curr Opin Urol; 2019 Sep; 29(5):540-541. PubMed ID: 31305272
    [No Abstract]   [Full Text] [Related]  

  • 18. Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor-based Dual Combination Therapy.
    Graafland NM; Szabados B; Tanabalan C; Kuusk T; Mumtaz F; Barod R; Nicol D; Boleti E; Powles T; Haanen JB; Bex A
    Eur Urol Oncol; 2022 Jun; 5(3):373-374. PubMed ID: 34933813
    [No Abstract]   [Full Text] [Related]  

  • 19. A Swinging Pendulum: Bringing Back Cytoreductive Nephrectomy in the Era of Immune Checkpoint Inhibition.
    Pallauf M; Ged Y; Singla N
    Eur Urol Oncol; 2022 Oct; 5(5):585-586. PubMed ID: 35965196
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
    Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
    Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.